Variant Factor Xa Proteins Modulating Hemostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current coagulation cascade therapies face challenges in modulating hemostasis effectively, particularly in conditions like hemophilia and thrombosis, where precise regulation of coagulation is needed, and existing coagulation factors often have limitations in activity and stability.
Innovation Solution
Development of variant Factor X/Xa zymogen/protease proteins with specific amino acid modifications that modulate the FX zymogen→protease transition pathway to produce a 'zymogen-like' FXa species, which can be used to enhance or reduce coagulation function as needed, including the use of nucleic acids encoding these variants and methods for their production and administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional coagulation factors are used to enhance coagulation, then coagulation function is improved, but activity and stability are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues in Factor X (positions 16, 17, and 194) to alter the protein's structural and functional parameters. These mutations create a zymogen-like FXa species with prolonged half-life and enhanced stability while maintaining coagulation activity, directly resolving the contradiction between coagulation function and duration of action.
Solution Approach 2:
The invention creates a composite molecular structure by combining the Factor X protein backbone with specific amino acid modifications at critical positions. This composite approach integrates the coagulation function of FXa with the stability characteristics of the modified zymogen-like structure, achieving both enhanced coagulation function and prolonged duration of action.
2Object-affected harmful factors
If coagulation is enhanced for hemophilia treatment, then bleeding is reduced, but risk of thrombosis increases
Solution Approach 1:
The patent introduces dynamics by creating a modifiable coagulation factor that can be adjusted in its activity level. The zymogen-like FXa variant provides a balanced approach to coagulation enhancement, allowing for controlled activation that reduces bleeding without excessive thrombosis risk, as the modified structure enables fine-tuned regulation of coagulation function.
Solution Approach 2:
By changing the amino acid parameters at positions 16, 17, and 194, the patent creates a Factor X variant with optimized coagulation properties. These parameter changes result in a protein that enhances coagulation function sufficiently to treat bleeding disorders while maintaining stability that prevents excessive thrombosis, resolving the contradiction between reducing bleeding and controlling thrombosis risk.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The variant Factor X/Xa proteins effectively modulate hemostasis by providing enhanced coagulation in deficiencies and reduced coagulation in excess, demonstrating prolonged activity and stability, thereby addressing the limitations of traditional coagulation therapies.
Implementation Method 1
The coagulation enzymes circulate in blood as inactive precursors, zymogens, that require proteolytic cleavage for activation. The conversion of the zymogen to serine protease requires cleavage following Arg15 (typically the bond between Arg15 and Ile16)
Implementation Method 2
N-terminal insertion leads to the formation of a salt bridge between the α-NH2 group of Ile16 and Asp194 in the interior of the catalytic domain
Implementation Method 3
The enzymes of coagulation are trypsin-like enzymes that belong to the S1 peptidase family of proteases. The coagulation proteases contain catalytic domains that are highly homologous to each other and to the ancestral serine proteases of digestion
Data Source
AI summary
Factor Xa variants and methods of use thereof are disclosed.